CONNECTIVE TISSUE DISEASES Trial of SLE therapies in real-world settings

    loading  Checking for direct PDF access through Ovid

Abstract

Allocation of therapy for systemic lupus erythematosus (SLE) remains complex, as most drugs used to treat this disease are used off-label—a situation compounded by the emergence of new therapeutics. In this rapidly changing clinical setting, organ-specific therapeutic guidelines might be useful for ‘real world’ management of patients with SLE.

Related Topics

    loading  Loading Related Articles